- Home
- AGEN vs KNDI Comparison
AGEN vs KNDI Comparison
Compare AGEN & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- KNDI
- Stock Information
- Founded
- AGEN 1994
- KNDI 2002
- Country
- AGEN United States
- KNDI China
- Employees
- AGEN N/A
- KNDI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- KNDI Auto Manufacturing
- Sector
- AGEN Health Care
- KNDI Consumer Discretionary
- Exchange
- AGEN Nasdaq
- KNDI Nasdaq
- Market Cap
- AGEN 87.7M
- KNDI 96.3M
- IPO Year
- AGEN 2000
- KNDI N/A
- Fundamental
- Price
- AGEN $5.16
- KNDI $1.11
- Analyst Decision
- AGEN Buy
- KNDI
- Analyst Count
- AGEN 4
- KNDI 0
- Target Price
- AGEN $13.00
- KNDI N/A
- AVG Volume (30 Days)
- AGEN 1.6M
- KNDI 80.6K
- Earning Date
- AGEN 08-07-2025
- KNDI 06-17-2025
- Dividend Yield
- AGEN N/A
- KNDI N/A
- EPS Growth
- AGEN N/A
- KNDI N/A
- EPS
- AGEN N/A
- KNDI N/A
- Revenue
- AGEN $99,524,000.00
- KNDI $127,569,613.00
- Revenue This Year
- AGEN $14.49
- KNDI N/A
- Revenue Next Year
- AGEN N/A
- KNDI N/A
- P/E Ratio
- AGEN N/A
- KNDI N/A
- Revenue Growth
- AGEN N/A
- KNDI 3.21
- 52 Week Low
- AGEN $1.38
- KNDI $0.89
- 52 Week High
- AGEN $18.74
- KNDI $2.25
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- KNDI 43.83
- Support Level
- AGEN $5.06
- KNDI $1.03
- Resistance Level
- AGEN $6.35
- KNDI $1.15
- Average True Range (ATR)
- AGEN 0.59
- KNDI 0.06
- MACD
- AGEN 0.12
- KNDI 0.00
- Stochastic Oscillator
- AGEN 65.00
- KNDI 58.82
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.